期刊文献+

贝伐单抗治疗恶性肿瘤相关不良反应的发生机制及处理方法 被引量:13

原文传递
导出
摘要 肿瘤生长和增殖过程中需要新生血管的形成,而血管内皮生长因子(VEGF)在其中起重要的作用。VEGF家族包括VEGF-A、VEGF—B、VEGF—C、VEGF—D等多个相关因子,而在肿瘤新生血管形成中最重要的是VEGF—A因子,它可促进血管内皮细胞生长、增殖,并与血管内皮细胞产生的生长因子受体相结合,激活下游信号转导通路,最终促进新生血管的生成。
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2010年第7期481-486,共6页 Chinese Journal of Oncology
关键词 贝伐单抗 肿瘤 危险陛评估 Bevacizumab Neoplasms Risk assessment
  • 相关文献

参考文献8

  • 1Mourad JJ,des Guetz G,Debhabi H,et al.Blood pressure rise following angiogenesis inhibition by bevacizumab:a crucial role for microcirculation.Ann Oncol,2008,19:927-934.
  • 2Nalluri SR,Chu D,Keresztes R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis.JAMA,2008,300:2277-2285.
  • 3Hapani S,Chu D,Wu S.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis.Lancet Oncol,2009,10:559-568.
  • 4徐建明.结直肠癌分子靶向治疗面临的若干问题[J].中华肿瘤杂志,2009,31(5):321-323. 被引量:3
  • 5Saif MVV,Elfiky A,Salem RR.Gastrointestinal perforation due to bevacizumab in colorectal cancer.Ann Surg Oncol,2007,14:1860-1869.
  • 6Badgwell BD,Camp ER,Feig B,et al.Management of bevacizumab-associated bowel perforation; a case series and review of the literature.Ann Oncol,2008,19:577-582.
  • 7Shord SS,Bressler LR,Tiemery LA,et al.Understanding and managing the possible adverse effects associated with bevacizumab.Am J Health Syst Pharm,2009,66:999-1013.
  • 8Reidy DL,Chung KY,Timoney JP,et al.Bevacizumab 5 mg/kg can be infused safely over 10 minutes.J Clin Oncol,2007,25:2691-2695.

二级参考文献18

  • 1Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 2006, 42:2212-2221.
  • 2Poston G, Adam R, Vauthey JN, et al. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Chn Oncol, 2006, 24:2702-2706.
  • 3Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol, 2008, 26:5326-5334.
  • 4Tejpar S, Peeters M, Humblet Y, et al. Dose-escalation study using up to twice the standard dose of eetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study) : preliminary data. J Clin Oncol, 2007, 25 : 172s ( abstr 4037).
  • 5Van Cutsem E, Lang I, D'haens G, et al. Kras status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuxmab: the CRYSTAL experience. J Clin Oncol, 2008, 26 :Ss (abstr 2).
  • 6Bokemeyer C, Bondarenko I, Hartmann JT, et al. Kras status and efficacy of first-line treatment of patients with metastatic eolorectal cancer (mCRC) treated with FOLFOX with or without cetuxmab: the OPUS experience. J Clin Oneol, 2008, 26: 178s ( abstr 4000).
  • 7Carcereny E, Castellvi-Bel S, Alonoso V, et al. EGFR polymorphism as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab. J Clin Oncol, 2008, 26:209s( abstr 4124).
  • 8Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359 : 1757-1765.
  • 9Lievre A, Bachet JB, Boiqe V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with eetuximab. J Clin Oncol, 2008, 26:374-379.
  • 10Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest, 2006, 10:2610-2621.

共引文献2

同被引文献82

引证文献13

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部